Evidence map›Paper›PMID 32255263›Full record

ArticleMolecular oncology2020

RAD52 S346X variant reduces breast cancer risk in BRCA2 mutation carriers.

Kajal Biswas, Shyam K Sharan

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Transcriptomics and Proteomics Analysis of the Liver ofInternational journal of molecular sciences · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kajal BiswasMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Shyam K SharanMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.ORCID 0000-0002-9333-870X
National Institutes of Health · US

Funding

Identification of genetic interactors of BRCA2ZIABC011311 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARAN, SHYAM · 2010 to 2025
$13.2M
Functional Evaluation of BRCA2 Variants on TumorigenesisZIABC010387 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARAN, SHYAM · 2009 to 2025
$12.5M
Functional Analysis of Variants Identified in Human Breast Cancer SusceptibilityZIABC011181 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARAN, SHYAM · 2009 to 2025
$11.6M
6 · The paper itself

Abstract

Adamson et al. report that BRCA2 mutation carriers inheriting RAD52 S346X variant have reduced breast cancer risk. The RAD52 S346X variant lacks the nuclear localization sequence, which mislocalizes the protein to the cytoplasm and renders it nonfunctional. Combined loss of BRCA2-mediated DNA repair by homologous recombination and RAD52-mediated single-strand annealing may result in cell death and reduce breast cancer risk. Comment on: https://doi.org/10.1002/1878-0261.12665.

Indexed as

Breast NeoplasmsBRCA2 ProteinCell Line, TumorDNA RepairGerm CellsHumansMutationRad52 DNA Repair and Recombination ProteinBRCA2 ProteinBRCA2 protein, humanRad52 DNA Repair and Recombination ProteinRAD52 protein, human

Identifiers

PMID32255263
PMCPMC7266267
OpenAlexW3014825046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.